title: PLGA-based nanoparticles: an overview of biomedical applications.
abstract: Poly(lactic-co-glycolic acid) (PLGA) is one of the most successfully developed biodegradable polymers. Among the different polymers developed to formulate polymeric nanoparticles, PLGA has attracted considerable attention due to its attractive properties: (i) biodegradability and biocompatibility, (ii) FDA and European Medicine Agency approval in drug delivery systems for parenteral administration, (iii) well described formulations and methods of production adapted to various types of drugs e.g. hydrophilic or hydrophobic small molecules or macromolecules, (iv) protection of drug from degradation, (v) possibility of sustained release, (vi) possibility to modify surface properties to provide stealthness and/or better interaction with biological materials and (vii) possibility to target nanoparticles to specific organs or cells. This review presents why PLGA has been chosen to design nanoparticles as drug delivery systems in various biomedical applications such as vaccination, cancer, inflammation and other diseases. This review focuses on the understanding of specific characteristics exploited by PLGA-based nanoparticles to target a specific organ or tissue or specific cells.
authors.affiliation: Université Catholique de Louvain, Louvain Drug Research Institute, Pharmaceutics and Drug Delivery, Avenue Mounier, B1 73.12, 1200 Brussels, Belgium.
authors.forename: Fabienne
authors.initials: F
authors.lastname: Danhier
authors.forename: Eduardo
authors.initials: E
authors.lastname: Ansorena
authors.forename: Joana M
authors.initials: JM
authors.lastname: Silva
authors.forename: Régis
authors.initials: R
authors.lastname: Coco
authors.forename: Aude
authors.initials: A
authors.lastname: Le Breton
authors.forename: Véronique
authors.initials: V
authors.lastname: Préat
mesh_terms: D000818:Animals; D001424:Bacterial Infections / Q000188:drug therapy; D001927:Brain Diseases / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy; D016503:Drug Delivery Systems; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D019344:Lactic Acid / Q000627:therapeutic use*; D050997:Nanomedicine / Q000379:methods; D053758:Nanoparticles / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy; D011100:Polyglycolic Acid / Q000627:therapeutic use*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D014611:Vaccination / Q000379:methods
chemical_list: D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid